BR112019002125A2 - composição de comprimidos de alta carga de fármacos para o tratamento do hiv - Google Patents

composição de comprimidos de alta carga de fármacos para o tratamento do hiv

Info

Publication number
BR112019002125A2
BR112019002125A2 BR112019002125-6A BR112019002125A BR112019002125A2 BR 112019002125 A2 BR112019002125 A2 BR 112019002125A2 BR 112019002125 A BR112019002125 A BR 112019002125A BR 112019002125 A2 BR112019002125 A2 BR 112019002125A2
Authority
BR
Brazil
Prior art keywords
tablet composition
high drug
hiv treatment
drug tablet
antiretroviral
Prior art date
Application number
BR112019002125-6A
Other languages
English (en)
Inventor
Reddy Bandi Parthasarathi
Podile Khadgapathi
Deviprasad Tiwari Sunil
Shetiya Prakash
Medum Balakrishnaiah
Original Assignee
Hetero Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Labs Limited filed Critical Hetero Labs Limited
Publication of BR112019002125A2 publication Critical patent/BR112019002125A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

refere-se a presente invenção a composições farmacêuticas anti-retrovirais que compreendem uma combinação de agentes anti-retrovirais, o seu processo de fabricação e uso das referidas composições para a prevenção, tratamento ou profilaxia de enfermidades causadas por retro-vírus, especificamente síndrome da imunodeficiência adquirida ou uma infecção pelo hiv.
BR112019002125-6A 2016-08-08 2017-07-28 composição de comprimidos de alta carga de fármacos para o tratamento do hiv BR112019002125A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641026995 2016-08-08
ININ201641026995 2016-08-08
PCT/IB2017/054593 WO2018029566A1 (en) 2016-08-08 2017-07-28 A high drug loaded tablet composition for treating hiv

Publications (1)

Publication Number Publication Date
BR112019002125A2 true BR112019002125A2 (pt) 2019-05-14

Family

ID=61162106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002125-6A BR112019002125A2 (pt) 2016-08-08 2017-07-28 composição de comprimidos de alta carga de fármacos para o tratamento do hiv

Country Status (5)

Country Link
US (1) US20190175509A1 (pt)
EP (1) EP3496710A4 (pt)
BR (1) BR112019002125A2 (pt)
WO (1) WO2018029566A1 (pt)
ZA (1) ZA201901004B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102058097B1 (ko) * 2011-07-07 2019-12-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 다루나비어 복합 제제
IN2013MU01749A (pt) * 2013-05-15 2015-06-26 Cipla Ltd

Also Published As

Publication number Publication date
US20190175509A1 (en) 2019-06-13
EP3496710A4 (en) 2020-03-18
ZA201901004B (en) 2019-11-27
WO2018029566A1 (en) 2018-02-15
EP3496710A1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
BR112019007931A2 (pt) composições antivirais para o tratamento de infecções ligadas ao coronavírus
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
IN2013MU01749A (pt)
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
BR112017017500A2 (pt) derivado de quinolina para uso no tratamento e prevenção de infecções virais
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019002734A2 (pt) tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
DOP2017000086A (es) Composiciones farmacéuticas de acción prolongada
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
UY38755A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
BR112019002125A2 (pt) composição de comprimidos de alta carga de fármacos para o tratamento do hiv
BR112019002132A2 (pt) composições anti-retrovirais
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.